The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Synovial sarcoma: Evaluation of response to treatment with gemcitabin and docetaxel.
Sausan Abouharb
No relevant relationships to disclose
Carla L. Warneke
No relevant relationships to disclose
Vinod Ravi
No relevant relationships to disclose
Joseph A. Ludwig
No relevant relationships to disclose
Alexander J. F. Lazar
No relevant relationships to disclose
Shreyaskumar Patel
Consultant or Advisory Role - GlaxoSmithKline; Johnson & Johnson; Novartis
Research Funding - Astex Therapeutics; Eisai; Infinity Pharmaceuticals; Johnson & Johnson; Morphotek; PharmaMar
Robert S. Benjamin
No relevant relationships to disclose
Dejka M. Araujo
No relevant relationships to disclose